NorthWest Biotherapeutics Inc (NWBO)

[Galzus Research]

Then your information is not up to date. EF14 read out OS in 2017. Other trials have come along reproducing the mOS of around 20 months.

And Optune is approved in the UK. It's just not reimbursed through NICE. This was because the results were not sufficient to justify reimbursement. Note that the median OS improvement shown in EF-14 are on par with what DCVax-L showed in the phase 3 publication.